Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous cerebrospinal fluid (aCSF) is a patient-derived biologic fluid harvested via lumbar puncture and reintroduced to the same patient for therapeutic or diagnostic purposes. It is primarily utilized as a highly biocompatible suspension medium for the delivery of cell therapies, such as mesenchymal stem cells (MSCs) in the treatment of Amyotrophic Lateral Sclerosis (ALS). Additionally, it is used as a convective infusate in convection-enhanced delivery (CED) protocols to enhance the visualization of deep brain structures like the basal ganglia during MRI-guided neurosurgery for Parkinson's disease. Its use minimizes the risk of immunological rejection and inflammation compared to synthetic vehicles. Experimental applications also include inducing thymus-mediated immune tolerance to brain antigens following surgical brain injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous cerebrospinal fluid.